By the end of this topic, the student should be able to:
Opioids are a class of compounds defined by their pharmacological activity, not their source or chemical structure.
The original, natural opioid is morphine. It is derived from the opium poppy (Papaver somniferum) seed pod resin, and it is an opioid receptor agonist (meaning it activates opioid receptors in the body).
Technically, opioids are drugs that have morphine-like effects, i.e., they activate opioid receptors, whereas opiates are compounds derived from the opium poppy.
So, morphine is an opioid and an opiate because it is an opioid receptor agonist and is derived from the opium poppy.
Fentanyl is an opioid (because it is an opioid receptor agonist) but not an opiate (it is synthetic, not a naturally occurring molecule in the opium poppy).
Opioids can be full agonists that, depending on the concentration, maximally activate opioid receptors, or partial agonists that only partially activate receptors, regardless of concentration.
In Canada, the regulatory status of opioids is addressed by the Controlled Drugs and Substances Act (CDSA) and the Narcotic Control Regulations.
The CDSA (2019) and its regulations provide a legal framework to make the production, sale, and possession of certain substances illegal. The regulations also outline:
The following is a list of opioids regulated in Canada.
In 2019, the Canadian Institute for Health Information reported that codeine was the most commonly prescribed opioid (56.1 percent) followed by oxycodone and hydromorphone (16.7 percent and 16.5 percent, respectively).
Unregulated opioids are produced outside the regulatory system. They are also referred to as illegal, illicit, black market, or bootleg.
In addition to unregulated opioids, regulated prescription opioids can be diverted for illegal sale after illegal importation, theft (e.g., from a pharmacy, home, or individual), or being obtained via prescription but sold to others instead.
It is difficult to determine which unregulated/illegal opioids are present in Canada at any given time.
Based on law enforcement seizures, testing of biological samples of opioid users, or pilot projects that test opioid user drug samples, several unregulated synthetic opioids have been identified in North America. For example, fentanyls have been detected, including 3-methylfentanyl, carfentanil, beta-hydroxyfentanyl, acetylfentanyl, and many others.
In addition, there are synthetic unregulated opioids that are not chemically related to fentanyl, including U-47700 and AH-7921. These numbered molecules were originally developed by pharmaceutical companies but never marketed. They have since been illegally synthesized for the unregulated market.
There are several ways to administer opioids. Routes of administration for opioids include the following:
Generally, the effects and adverse effects of opioids occur more quickly and intensely for injected versus inhaled/nasal versus oral.
© Course Author(s) and University of Waterloo
The increase in the number of cases of opioid-induced respiratory depression/overdose and opioid-related mortality has coincided with a change in illicit opioid use, from diverted prescription opioids, particularly OxyContin, and heroin, to unregulated synthetic fentanyl and its analogues.
To learn more about opioid potency and opioid overdose, see Module 1, Topic F.
Why does the unregulated opioid U-47700 have just letters and numbers, and not have a name like morphine, oxycodone, or fentanyl?
Feedback
U-47700 was developed by a pharmaceutical company (Upjohn). In the development process, companies test hundreds or thousands of molecules, so they don’t bother naming these, unless they decide to bring a drug to market.
Boom, M., Niesters, M., Sarton, E., Aarts, L., Smith, T. W., & Dahan, A. (2012). Non-analgesic effects of opioids: Opioid-induced respiratory depression. Current Pharmaceutical Design, 18, 5994–6004.
Canadian Institute for Health Information. (2019). Opioid prescribing in Canada—How are practices changing? https://www.cihi.ca/sites/default/files/document/opioid-prescribing-canada-trends-en-web.pdf
Brunton, L. L., Hilal-Dandan, R., & Knollmann, B. C. (2018). Goodman and Gilman’s the pharmacological basis of therapeutics (13 ed.). McGraw-Hill Education.
Canadian Institute for Health Information. (2019). Opioid prescribing in Canada: How are practices changing?. Ottawa, ON: CIHI
Controlled Drugs and Substances Act, SC 1996, c 19. Government of Canada, Justice Laws Website. https://laws-lois.justice.gc.ca/eng/acts/C-38.8/FullText.html
Franco F. (2018). Childhood abuse, complex trauma and epigenetics. PsychCentral. https://psychcentral.com/lib/childhood-abuse-complex-trauma-and-epigenetics/
Health Canada. (2018). Opioids list. Government of Canada. https://www.canada.ca/en/health-canada/services/drugs-health-products/reports-publications/medeffect-canada/list-opioids.html
Health Canada. (2019). Canada’s opioid crisis. Government of Canada. https://www.canada.ca/content/dam/hc-sc/documents/services/publications/healthy-living/canada-opioid-crisis.pdf
Katzung, B. G. (2018). Basic and clinical pharmacology (14 ed.). McGraw-Hill Education.
Macy, B. (2018). Dopesick: Dealers, doctors, and the drug company that addicted America. Little, Brown, and Company.
Narcotic Control Regulations, CRC, c 1041. Government of Canada, Justice Laws Website. https://laws-lois.justice.gc.ca/eng/regulations/C.R.C.,_c._1041/FullText.html
Sofalyi, S., Lavins, E. S., Brooker, I. T., Kaspar, C. K., Kucmanic, J., Mazzola, C. D., Mitchell-Mata, C. L., Clyde, C. L., Ricco, R. N., Appolonio, L. G., Goggin, C., Marshall, B., Moore, D., & Gilson, T. P. Unique structural/stereo-isomer and isobar analysis of novel fentanyl analogues in postmortem and DUID whole blood by UHPLC-MS-MS. Journal of Analytical Toxicology, 43, 673–687.
Solimini, R., Pichini, S., Pacifici, R., Busardo, F. P., & Giorgetti, R. (2018). Pharmacotoxicology of non-fentanyl derived new synthetic opioids. Frontiers in Pharmacology, 9, 654.